RenovoRx Data Acceptance Highlights Pancreatic Cancer Treatment Challenge
Event summary
- RenovoRx’s clinical data abstract, submitted by Moffitt Cancer Center, has been accepted for presentation at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting.
- The abstract explores the use of Trans-Arterial Micro-Perfusion (TAMP) therapy and metabolic imaging (FDG PET/CT) for pancreatic cancer treatment.
- The data focuses on addressing poor vascularity in locally advanced pancreatic cancer (LAPC) through targeted intra-arterial chemotherapy delivery.
- RenovoRx generated approximately $900,000 in revenue from RenovoCath sales during the first nine months of 2025.
The big picture
RenovoRx’s approach targets a significant unmet need in LAPC treatment, where traditional systemic chemotherapy often faces limitations due to poor vascularity. The company’s reliance on a novel drug-delivery platform and a combination product strategy introduces complexity and risk, but also the potential for improved patient outcomes and a differentiated market position. The SIR presentation provides a key data point in assessing the validity of this approach.
What we're watching
- Clinical Validation
- The SIR presentation’s data will be crucial in validating the TAMP platform’s efficacy and the utility of metabolic imaging in assessing treatment response, potentially impacting future development and regulatory pathways.
- Commercial Traction
- The continued adoption rate of RenovoCath, beyond the initial purchase orders, will indicate the viability of the standalone device and its role in broader clinical workflows.
- Regulatory Pathway
- The FDA’s ongoing evaluation of IAG, and any feedback received, will significantly influence the timeline and potential approval of RenovoRx’s combination drug-device product.
Related topics